On August 30, 2016, NASDAQ Listing Qualifications staff (Staff)
notified Medovex Corporation (Company) that it did not maintain
the minimum required level of stockholder equity, in violation of
Rule 5550(b).  Staff gave the Company until February 27, 2017 to
execute a plan to regain compliance with the Rule. After briefly
regaining compliance with the Rule in February 2017, the Company
again fell out of compliance in March, prompting Staff to issue
a delisting decision on May 17, 2017. The Company appealed the
decision. A hearing was held on February 24, 2017. Twice in July
2017, the Hearing Panel issued decisions that granted the Company
additional time to raise equity.  On November 14, 2017, the
Hearing Panel issued a delisting decision after the Company failed
to provide evidence of any additional upcoming or completed equity
raises. On November 28, 2017, the Company exercised its right to
appeal the Panel decision to the Nasdaq Listing and Hearing Review
Council (Council).  In the Companys brief to the Council, dated
December 8, 2017, the Company indicated that it was working to
close a transaction that it said would bring it back into sustained
compliance with Rule 5550. The Company further stated in its brief
that the Council should deem the Company's appeal to be withdrawn
if the Company did not inform the Council by January 5, 2017 that
it had closed the transaction. The Council received no such letter
from the Company. As such, the Council deemed withdrawn the Companys
appeal of the Hearing Panels decision to delist its securities.
The Council informed the Company of this determination on
January 8, 2018.